文献速递银屑病与炎症性皮肤病

银屑病患者序贯生物制剂治疗:一项为期12年的单中心回顾性观察研究

Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study.
PubMed 文献 · J Am Acad Dermatol · 2019-05-29

该研究回顾性观察了2006—2018年间195例银屑病患者,评估各生物制剂的药物生存期及影响因素。结果显示90.6%患者达到PASI较基线改善≥75%,基线PASI较高者更易转换治疗,生物制剂初治患者中乌司奴单抗药物生存期较长,跨类转换较类内转换药物生存期更长。

要点

  • 初治患者中乌司奴单抗药物生存期较长(>7.0年),经治患者无显著差异。

核心结论

  • 跨生物制剂类别转换可能提高药物生存期,但需前瞻性研究确认此转换策略。

研究设计与样本

  • 单中心回顾性观察研究,纳入2006—2018年195例银屑病患者,采用描述性统计、logistic回归、Kaplan-Meier生存曲线及多因素Cox模型分析。

主要发现

  • 90.6%患者达到PASI较基线改善≥75%。
  • 2018年最常用生物制剂为乌司奴单抗(47/169,27.8%)。
  • 初治患者中乌司奴单抗药物生存期>7.0年,经治患者中各生物制剂无显著差异。

关键数值与推荐

  • 药物生存期定义为从起始至停药的时间。

临床怎么用

  • 对基线PASI较高的银屑病患者,应预期可能需要转换生物制剂。
  • 生物制剂初治患者可考虑乌司奴单抗以获得较长药物生存期。
  • 需转换时,跨类转换可能优于类内转换,以延长药物生存期。

局限性

  • 单中心回顾性真实世界研究,数据不完全同质。
  • 需专门设计的前瞻性研究确认跨类转换策略的优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic therapy for psoriasis is effective but not always long-lasting and sometimes needs to be switched. OBJECTIVE: We aimed to evaluate the drug survival (ie, the time from initiation to discontinuation) of each biologic and the factors affecting survival to identify better switching strategies and improve drug survival. METHODS: In total, 195 psoriasis patients treated in our unit during 2006-2018 were retrospectively observed. Descriptive statistical analyses and logistic regression models were performed. Kaplan-Meier survival curves and multivariate Cox models adjusted for confounding variables were used to estimate and compare drug survival. RESULTS: Overall, 90.6% of patients achieved an ≥75% reduction in their baseline Psoriasis Area and Severity Index score. In 2018, the most frequently used biologic was ustekinumab (47/169, 27.8%). Patients with higher baseline Psoriasis Area and Severity Index scores were more likely to be switched (P = .0399, odds ratio 1.08). In naive patients, ustekinumab showed longer drug survival (>7.0 years), but in biologic-experienced patients, we found no significant differences in drug survival. Previous biologic therapies increased the need for switching (P = .014, hazard ratio 1.20). Switching between biologic classes yielded longer drug survival than switching within biologic classes (P = .003, hazard ratio 0.48). LIMITATIONS: As a single-center, retrospective real-life study, the data were not perfectly homogeneous. CONCLUSION: Switching between biologic classes might increase drug survival but retrospective studies designed ad hoc are needed to confirm this better switching strategy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Cozzani E, Wei Y, Burlando M, et al. Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study. J Am Acad Dermatol. 2019. PMID: 31150706. doi:10.1016/j.jaad.2019.05.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。